RevOpsis Therapeutics and Kemwell Biopharma Pvt. Ltd. have entered a strategic partnership to accelerate the development of RevOpsis’ lead candidate, RO-104, for the treatment of neovascular age-related macular degeneration (nAMD). The collaboration, announced on June 17, 2024, leverages Kemwell’s contract
Kemwell BioPharma, India’s largest biologics contract development and manufacturing organisation (CDMO), has announced the implementation of the Veeva Vault Quality Management System (QMS) across its development and manufacturing operations. Deepak Gupta, vice president of quality at Kemwell, said, “Veeva is
Kemwell Biopharma is a company operating in the pharmaceutical industry. Kemwell is a contract biologics development and CMO company providing services to global biopharmaceutical organizations. Kemwell facilities, located in Bangalore, India, are designed and developed with technological support from a
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
